Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Ltd has announced the issuance of 4,800,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and support its ongoing development projects. The issuance of these securities is expected to strengthen Immutep’s financial position, potentially impacting its market presence and providing additional resources for its research and development initiatives.
More about Immutep Ltd
Immutep Ltd is a biotechnology company that focuses on developing immunotherapy treatments for cancer and autoimmune diseases. The company is involved in the research and development of innovative therapies that aim to harness the body’s immune system to fight diseases, positioning itself as a key player in the biotech industry.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $256.4M
See more data about IMM stock on TipRanks’ Stock Analysis page.